Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Oct;24(5):750-758.
doi: 10.1007/s11307-022-01724-2. Epub 2022 Apr 11.

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

Kathia De Man  1 , Sarah Piron  2 , Nick Van Laeken  3 , Louke Delrue  4 , Valérie Fonteyne  5 , Nicolaas Lumen  6 , Bliede Van den Broeck  3 , Ken Kersemans  3 , Piet Ost  7   8 , Vanessa Schelfhout  3
Affiliations
Observational Study

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

Kathia De Man et al. Mol Imaging Biol. 2022 Oct.

Abstract

Purpose: In this study, we evaluated the impact of 18F-PSMA-11 PET/CT on the patient management plan in patients with primary or recurrent disease. Furthermore, a correlation between PET findings and other modalities was performed.

Procedures: In this prospective observational study, 60 prostate cancer patients (9 primary staging, 51 biochemical recurrence) were imaged with 18F-PSMA-11 PET/CT. Pre- and post-scan questionnaires were completed by the treating physician to observe changes in therapy intent. Follow-up data (histological confirmation, MRI imaging, and PSA values after radiotherapy without implementation of systemic therapy) was correlated with the 18F-PSMA-11 findings.

Results: The patient-based detection rate was 82% and a management change was seen in 52% of the cases. The heterogeneous characteristics of the included patients resulted in a widely varying treatment change, mostly originating from an increase of disease extent on 18F-PSMA-11 PET/CT.

Conclusion: 18F-PSMA-11 PET/CT showed to be a highly promising method for the detection of prostate cancer lesions.

Keywords: 18F-PSMA-11; Human; Management; PET/CT; Prostate cancer.

PubMed Disclaimer

References

    1. N. Mottet, P. Cornford, R.C.N. van den Bergh, E. Briers, M. De Santis, S. Fanti, S.Gilessen, J. Grummet, A. M. Henry, T. B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, I.G. Schoots, D. Tilki, T. W. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer.
    1. Corfield J, Perera M, Bolton D, Lawrentschuk N (2018) 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519–527 - DOI
    1. Hofman MS et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216 - DOI
    1. Murthy, V. et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J. Clin. Oncol. JCO.20.03282 (2021) https://doi.org/10.1200/jco.20.03282 .
    1. Luiting HB et al (2020) Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int 125:206–214 - DOI

Publication types

MeSH terms

LinkOut - more resources